Celebrex PRECISION Trial: 'Herculean' Effort, But Missing Information Bugs US FDA Panel

Pfizer study finds Celebrex's CV risk comparable to naproxen and ibuprofen, but advisory committee wanted data on confounding factors and reasons for high dropout.